TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Rhythm Biosciences Ltd. ( (AU:RHY) ).
Rhythm Biosciences Ltd. announced the issuance of 2,193,001 unquoted equity securities under an employee incentive scheme. This move is part of the company’s strategy to incentivize and retain talent, potentially enhancing its operational capabilities and competitive positioning in the biotechnology sector.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. operates in the biotechnology industry, focusing on the development of medical diagnostics. The company is primarily engaged in creating innovative products for early detection and monitoring of diseases, with a market focus on improving patient outcomes through advanced diagnostic solutions.
Average Trading Volume: 348,097
Technical Sentiment Signal: Buy
Current Market Cap: A$28.34M
For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.